PV Bulletin

Unapproved ibutamoren capsules (MK-677) found to contain undisclosed anabolic steroid

TGA warns that unapproved ibutamoren capsules (MK-677) contain an undisclosed anabolic steroid, posing serious health risks.

Primary source: https://www.tga.gov.au/news/safety-alerts/unapproved-ibutamoren-capsules-mk-677-found-contain-undisclosed-anabolic-steroid

PV Impact Brief

Urgency: HighConfidence: high

What changed

TGA published a safety alert warning that unapproved ibutamoren capsules (MK-677) contain an undisclosed anabolic steroid.

Why it matters

The presence of an undisclosed anabolic steroid poses serious health risks, including potential adverse effects from unregulated ingredients.

Action needed

Consumers must stop taking the product immediately and return remaining capsules to a pharmacy for safe disposal.

Relevant for
Regulatory Intelligence LeadSignal Management Lead
Processes impacted
Signal ManagementLabeling
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Regulatory action details

Action type
Safety Alert
Publication date
2026-06-04
Safety issue
Unapproved ibutamoren capsules (MK-677) were found to contain an undisclosed anabolic steroid, posing serious health risks.

Affected products

  • Ibutamoren capsules (MK-677)

PV internal implications

Consumers should stop taking the product immediately and take any remaining capsules to their local pharmacy for safe disposal.

View regulator source

Evidence and confidence

Confidence: highSource updated: Jun 4, 2026

Full briefing

Practical implication

Consumers must stop taking the product immediately and return remaining capsules to a pharmacy for safe disposal.

The TGA issued a safety alert on 4 June 2026 regarding unapproved ibutamoren capsules (MK-677) found to contain an undisclosed anabolic steroid. Consumers are advised to stop use immediately and dispose of remaining capsules at a pharmacy.

What changed: TGA published a safety alert warning that unapproved ibutamoren capsules (MK-677) contain an undisclosed anabolic steroid.

Why it matters: The presence of an undisclosed anabolic steroid poses serious health risks, including potential adverse effects from unregulated ingredients.

Practical implication: Consumers must stop taking the product immediately and return remaining capsules to a pharmacy for safe disposal.

View original source

Published from the Firecrawl agent regulatory extraction pipeline.

#TGA#Safety Signals#firecrawl-agent#regulatory-extraction#Other#Safety Alert

Related updates for your role

publicFDA · USA · Updated Aug 28, 2026

FDA Approves Mimrylo for Polycythemia Vera Treatment

Urgency: High

Patients will be treated with an initial dose of 19 mg of Mimrylo, administered weekly, with careful monitoring to maintain hematocrit levels below 45%. The operation of post-marketing surveillance will be affected due to the introduction of this new drug.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Labeling Lead
verifiedRegulatory action: Latest
Read impact briefarrow_forward
publicMHRA · UK · Updated Aug 28, 2026

Record Ketamine Seizures Indicate Safety Concerns

Urgency: High

Monitor and evaluate the drug misuse trends and health impacts associated with ketamine, focusing on the increase in seizures as part of public health and law enforcement strategies.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicEMA · European Union · Updated Aug 28, 2026

PSUSA/00001088/202512 - Safety Update Amendments for Dimenhydrinate

Urgency: High

Implement the updated product information by November 5, 2026, ensuring that all labeling and documentation includes the new warnings and risk profiles.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicEuropean Medicines Agency · European Union · Updated Aug 28, 2026

Choline Salicylate PSUSA/00000732/202512 - Safety Update Assessment

Urgency: High

Implement new labeling requirements for choline salicylate products by November 5, 2026, including specific warnings as outlined.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward